SUV39H1

SUV39H1
National Center for Biotechnology Information, U.S. National Library of Medicine · Public domain · source
Name	SUV39H1
Organism	Homo sapiens

SUV39H1 is a human histone lysine methyltransferase that catalyzes trimethylation of histone H3 at lysine 9 (H3K9me3), contributing to transcriptional repression and heterochromatin formation. It was characterized through genetic and biochemical studies alongside model organism research, and it functions within multi-protein complexes that link chromatin state to nuclear architecture. Research on SUV39H1 intersects with studies of development, aging, cancer, and epigenetic therapies.

Introduction

SUV39H1 was identified following comparative studies with Drosophila melanogaster and Schizosaccharomyces pombe chromatin regulators and was named in the context of mammalian SET-domain methyltransferases. Early work connected SUV39H1 to pericentric heterochromatin and silencing phenomena observed in experiments at institutions such as Cold Spring Harbor Laboratory and universities including Harvard University and University of Cambridge. Subsequent collaborations linked SUV39H1 function to pathways studied at organizations like National Institutes of Health and Max Planck Society.

Structure and enzymatic activity

SUV39H1 contains a conserved SET domain characteristic of the SET family of methyltransferases, a pre-SET region, and an N-terminal chromodomain that mediates binding to methylated histone marks. Structural analyses have parallels with crystallographic studies performed at facilities such as European Synchrotron Radiation Facility and Diamond Light Source, and comparisons involve proteins studied in Protein Data Bank submissions. The enzyme uses S-adenosylmethionine as a methyl donor in reactions analogous to those catalyzed by other SET-domain enzymes characterized in reports from Weizmann Institute of Science. Catalytic residues were defined by mutational studies performed in laboratories at Massachusetts Institute of Technology and Stanford University.

Regulation and interaction partners

SUV39H1 activity is regulated by post-translational modifications and by interactions with adaptor proteins, chromatin readers, and chromatin remodelers. Known partners include HP1 family members originally discovered in studies at European Molecular Biology Laboratory, the histone deacetylase complexes described in work from Yale University, and cofactors identified in proteomic surveys conducted at Broad Institute. SUV39H1 recruitment is influenced by interactions with transcription factors characterized in research from Columbia University and by non-coding RNA associations investigated at University of Oxford. Ubiquitin ligases and SUMO pathway components reported from Cold Spring Harbor Laboratory and Max Planck Institute modulate SUV39H1 stability.

Biological functions and roles in chromatin

SUV39H1 establishes H3K9me3 marks that serve as binding sites for chromodomain-containing proteins involved in constitutive heterochromatin at centromeres and telomeres, processes examined in cell biology studies at European Molecular Biology Laboratory, Fred Hutchinson Cancer Research Center, and Johns Hopkins University. SUV39H1 contributes to genomic stability, suppression of transposable elements, and regulation of developmental gene programs studied in developmental biology labs at Carnegie Institution for Science and University of California, San Francisco. Its role in facultative heterochromatin has been analyzed in connection with X-chromosome inactivation research performed at Cold Spring Harbor Laboratory and imprinting studies at The Salk Institute. Cross-talk between SUV39H1-mediated methylation and DNA methylation pathways has been explored in epigenetics programs at ETH Zurich and Institute of Cancer Research.

Implications in disease and therapeutic potential

Altered SUV39H1 expression or mutation has been implicated in oncogenesis, with links to hematological malignancies and solid tumors reported by clinical groups at Memorial Sloan Kettering Cancer Center and Mayo Clinic. SUV39H1 dysregulation affects pathways studied in cancer biology at Dana-Farber Cancer Institute and influences responses to DNA damage therapies developed at European Institute of Oncology. Given its enzymatic activity, SUV39H1 has been evaluated as a target for small-molecule inhibitors in drug discovery programs at pharmaceutical companies and translational centers including GlaxoSmithKline and Novartis. Connections to aging and neurodegeneration have been investigated in research from Buck Institute for Research on Aging and McGill University Health Centre.

Experimental studies and model organisms

Functional insights derive from knockout and knockdown studies in mouse models generated at institutions like Jackson Laboratory and phenotype analyses conducted at Wellcome Trust Sanger Institute. Comparative studies in Drosophila melanogaster Su(var)3-9 mutants and in Schizosaccharomyces pombe Clr4 orthologs provided foundational models used in laboratories at University of Basel and University of Tokyo. Cell-based assays in human lines performed at National Cancer Institute and high-throughput screens at Broad Institute elucidated interaction networks. Chromatin immunoprecipitation, mass spectrometry, and imaging studies employing resources at European Molecular Biology Laboratory and Institute Pasteur have mapped SUV39H1 distribution and dynamics.

Category:Human proteins